venetoclax + lenalidomide + dexamethasone

This is a **combination regimen** comprising three drugs: venetoclax (a selective, orally bioavailable small-molecule B-cell lymphoma 2 [BCL-2] inhibitor), lenalidomide (an immunomodulatory derivative of thalidomide and angiogenesis inhibitor), and dexamethasone (a synthetic corticosteroid). Each agent has a distinct mechanism, and together they are investigated primarily for the treatment of relapsed/refractory multiple myeloma. Venetoclax induces apoptosis in cancer cells overexpressing BCL-2, which is crucial in some myeloma subtypes (notably t(11;14)). Lenalidomide modulates the immune system and inhibits angiogenesis, impairing tumor cell proliferation and microenvironment support. Dexamethasone reduces inflammation and suppresses immune/stress responses, and is commonly used to mitigate chemotherapy side effects and contribute direct antitumor effects. The combination is not approved as a fixed-dose product but is under clinical investigation, particularly in relapsed or refractory multiple myeloma[1].